Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use

US9988443B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• John Trauger · Cambridge, US
• Andrei I. Voznesensky · Town of West Hartford, US
• Julia Neugebauer · Munich, DE
• Steffen Runz · Heidelberg, DE

Key dates

• Filing date: Aug 6, 2015
• Grant date: Jun 5, 2018
• Expiry date: Dec 2, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.